samedan logo
 
 
spacer
home > pmps > spring 2017 > security breach
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Security Breach

Approximately 40% of all pharmaceutical products available in the US are manufactured outside of the country. It is thought that 80% of the active ingredients in drugs are made and delivered from all over the world, and these must meet the country-specific regulatory requirements of the locations in which they are going to be sold. This highlights the complexity of the industry’s supply chain.

Like many high-value commodities, pharmaceuticals are attractive to criminals – whether they are online hackers or opportunistic individuals who hijack a truck and remove its goods – with no concern whether they are life-saving drugs, prescription medication or lifestyle products.

Negating threats means thoroughly assessing your entire distribution network to determine penetration points. This can include screening vendors to ensure that they have the proper cybersecurity measures in place; scrutinising physical vulnerabilities along the route where goods can be tampered with; and identifying countries and regions with high risks for disruptions to business continuity that can potentially impact your ability to get products from point A to B.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Ward serves as Vice President for the Global Intellectual Property Protection division at Pinkerton, a global provider of corporate risk management services including security consulting, investigations, executive protection, employment screening, protective intelligence and more.
spacer
Steve Ward
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement